Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports

Bevacizumab-Induced Thrombotic Microangiopathy (TMA) in Metastatic Lung Adenocarcinoma Patients Receiving Nivolumab Combined with Bevacizumab, Carboplatin and Paclitaxel: Two Case Reports

Anti-programmed death-1 (PD-1)/programmed death ligand 1 (PD-L1) immune checkpoint inhibitors (ICIs), combined with bevacizumab and platinum-based chemotherapy, have shown promising efficacy in treating metastatic non-squamous cell lung cancer in phase 3 clinical trials. However, drug-induced nephro...

Full description

Bibliographic Details
Main Authors: Ping-Chih Hsu, Tai-Di Chen, Tsung-Yu Tsai, Cheng-Ta Yang
Format: Article
Language:English
Published: MDPI AG 2023-01-01
Series:Clinics and Practice
Subjects:
bevacizumab
proteinuria
thrombotic microangiopathy (TMA)
immunotherapy
nivolumab
ant-PD-1
Online Access:https://www.mdpi.com/2039-7283/13/1/18

Internet

https://www.mdpi.com/2039-7283/13/1/18

Similar Items